RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl

The underpowered trial was negative but contained a signal of improvement in CV outcomes, Amit Khera says.

Related Keywords

United States ,San Diego ,California ,Japan ,Tokyo ,Dallas ,Texas ,Chicago ,Illinois ,La Jolla ,American ,Amit Khera ,Pam Taub ,Hiroyuki Daida ,Phd Juntendo University ,Md Uc San Diego Health ,American Heart Association ,Md Ut Southwestern Medical Center ,Juntendo University ,Medical Center ,Diego Health ,